Ionis Pharmaceuticals (IONS) Competitors $29.57 +0.47 (+1.62%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IONS vs. BIIB, UTHR, BMRN, INCY, NBIX, EXEL, EXAS, RGEN, HALO, and MDGLShould you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Ionis Pharmaceuticals vs. Biogen United Therapeutics BioMarin Pharmaceutical Incyte Neurocrine Biosciences Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Ionis Pharmaceuticals (NASDAQ:IONS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Does the MarketBeat Community prefer IONS or BIIB? Biogen received 1114 more outperform votes than Ionis Pharmaceuticals when rated by MarketBeat users. Likewise, 71.41% of users gave Biogen an outperform vote while only 60.33% of users gave Ionis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformIonis PharmaceuticalsOutperform Votes70460.33% Underperform Votes46339.67% BiogenOutperform Votes181871.41% Underperform Votes72828.59% Is IONS or BIIB more profitable? Biogen has a net margin of 16.87% compared to Ionis Pharmaceuticals' net margin of -64.25%. Biogen's return on equity of 14.98% beat Ionis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Ionis Pharmaceuticals-64.25% -100.05% -15.70% Biogen 16.87%14.98%8.76% Do analysts recommend IONS or BIIB? Ionis Pharmaceuticals currently has a consensus target price of $56.72, suggesting a potential upside of 91.82%. Biogen has a consensus target price of $211.37, suggesting a potential upside of 76.86%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Biogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ionis Pharmaceuticals 1 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.70Biogen 0 Sell rating(s) 18 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.42 Do institutionals and insiders hold more shares of IONS or BIIB? 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.7% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor IONS or BIIB? In the previous week, Biogen had 10 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 30 mentions for Biogen and 20 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 0.91 beat Ionis Pharmaceuticals' score of 0.83 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 11 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 16 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, IONS or BIIB? Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIonis Pharmaceuticals$705.14M6.67-$366.29M-$3.04-9.73Biogen$9.68B1.81$1.63B$11.1910.68 Which has more risk and volatility, IONS or BIIB? Ionis Pharmaceuticals has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. SummaryBiogen beats Ionis Pharmaceuticals on 12 of the 19 factors compared between the two stocks. Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IONS vs. The Competition Export to ExcelMetricIonis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.70B$6.59B$5.41B$7.70BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-9.737.0522.1818.31Price / Sales6.67273.45397.31107.09Price / CashN/A65.6738.2034.62Price / Book7.996.506.834.25Net Income-$366.29M$142.50M$3.20B$247.51M7 Day Performance4.12%8.32%5.77%6.86%1 Month Performance-8.37%-5.61%-4.32%-2.95%1 Year Performance-29.33%0.11%17.88%5.17% Ionis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IONSIonis Pharmaceuticals3.9595 of 5 stars$29.57+1.6%$56.72+91.8%-30.3%$4.70B$705.14M-9.73800Upcoming EarningsBIIBBiogen4.7622 of 5 stars$116.49-1.8%$213.15+83.0%-40.8%$17.05B$9.68B10.418,720Upcoming EarningsAnalyst ForecastNews CoverageUTHRUnited Therapeutics4.9284 of 5 stars$284.25-0.2%$395.67+39.2%+25.1%$12.77B$2.88B12.48980Upcoming EarningsInsider TradePositive NewsBMRNBioMarin Pharmaceutical4.8897 of 5 stars$58.65-0.9%$94.00+60.3%-31.2%$11.19B$2.85B26.663,080INCYIncyte4.8689 of 5 stars$56.80-2.4%$74.69+31.5%+14.0%$10.99B$4.24B210.382,320Upcoming EarningsAnalyst ForecastNews CoverageNBIXNeurocrine Biosciences4.8553 of 5 stars$100.68-0.7%$161.86+60.8%-23.9%$9.96B$2.36B30.601,200Upcoming EarningsAnalyst ForecastAnalyst RevisionEXELExelixis4.2982 of 5 stars$35.59-1.7%$37.59+5.6%+56.9%$9.96B$2.17B20.111,220Upcoming EarningsPositive NewsEXASExact Sciences4.2711 of 5 stars$43.10+3.7%$69.25+60.7%-27.9%$8.01B$2.76B-7.746,400Upcoming EarningsAnalyst RevisionNews CoverageRGENRepligen4.5407 of 5 stars$131.64+1.3%$176.82+34.3%-13.5%$7.39B$634.44M-258.122,020Upcoming EarningsGap UpHALOHalozyme Therapeutics4.416 of 5 stars$57.29-2.6%$62.89+9.8%+51.5%$7.08B$1.02B16.70390News CoverageMDGLMadrigal Pharmaceuticals4.482 of 5 stars$295.02-2.2%$378.44+28.3%+56.3%$6.51B$180.13M-11.7690Analyst ForecastPositive News Related Companies and Tools Related Companies BIIB Competitors UTHR Competitors BMRN Competitors INCY Competitors NBIX Competitors EXEL Competitors EXAS Competitors RGEN Competitors HALO Competitors MDGL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IONS) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
